2023
Challenges in Estimating the Effectiveness of COVID-19 Vaccination Using Observational Data
Hulme W, Williamson E, Horne E, Green A, McDonald H, Walker A, Curtis H, Morton C, MacKenna B, Croker R, Mehrkar A, Bacon S, Evans D, Inglesby P, Davy S, Bhaskaran K, Schultze A, Rentsch C, Tomlinson L, Douglas I, Evans S, Smeeth L, Palmer T, Goldacre B, Hernán M, Sterne J. Challenges in Estimating the Effectiveness of COVID-19 Vaccination Using Observational Data. Annals Of Internal Medicine 2023, 176: m21-4269. PMID: 37126810, PMCID: PMC10152408, DOI: 10.7326/m21-4269.Peer-Reviewed Original ResearchConceptsCOVID-19 vaccineRandomized trialsObservational studyCOVID-19 vaccinationDuration of protectionBooster vaccinationFirst doseTrial emulationNew virus variantsVaccinated personsEligible personsVaccine rolloutVaccinationTarget trialsVirus variantsTrialsVaccineTime-varying variablesBaselineRobust evidenceSingle trial approachRapid uptakePersonsConfoundersDose
2022
Safety of COVID-19 vaccination and acute neurological events: A self-controlled case series in England using the OpenSAFELY platform
Walker JL, Schultze A, Tazare J, Tamborska A, Singh B, Donegan K, Stowe J, Morton CE, Hulme WJ, Curtis HJ, Williamson EJ, Mehrkar A, Eggo RM, Rentsch CT, Mathur R, Bacon S, Walker AJ, Davy S, Evans D, Inglesby P, Hickman G, MacKenna B, Tomlinson L, Ca Green A, Fisher L, Cockburn J, Parry J, Hester F, Harper S, Bates C, Evans SJ, Solomon T, Andrews NJ, Douglas IJ, Goldacre B, Smeeth L, McDonald HI. Safety of COVID-19 vaccination and acute neurological events: A self-controlled case series in England using the OpenSAFELY platform. Vaccine 2022, 40: 4479-4487. PMID: 35715350, PMCID: PMC9170533, DOI: 10.1016/j.vaccine.2022.06.010.Peer-Reviewed Original ResearchConceptsGuillain-Barré syndromeAcute neurological eventsBell's palsyCOVID-19 vaccinationTransverse myelitisChAdOx1 vaccineOpenSAFELY platformFirst doseNeurological eventsRate of GBSSelf-controlled case series designIncidence rate ratiosPrimary care dataRare adverse eventsSelf-controlled case seriesConditional Poisson regressionCOVID-19 vaccineCase series designBNT162b2 vaccineesChAdOx1 vaccinationVaccine recipientsAdverse eventsHospital admissionCase seriesAbsolute risk